Capstone Therapeutics (CAPS) Misses Q1 EPS by 2c

Capstone Therapeutics (NASDAQ: CAPS) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• UBS: 'We Believe Dollar Tree (DLTR) is Turning From a Transformation to a Growth Story'
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)